Moxetumomab pasudotox is a CD22-targeted immunotoxin.
-
-
ASH 2020 — AML: Black race is tied to poor survival Racial disparities in cancer outcomes remain a challenge.
-
Draft NICE guidance recommends acalabrutinib for untreated CLL The draft guidance is open for public consultation until January 11, 2021
-
NICE approves venetoclax plus obinutuzumab for untreated CLL Approved for use in adults with and without a 17p deletion or TP53 mutation
-
AML: patient and physician priorities regarding treatment often misalign A multistakeholder perspective on shared decision-making.
-
Tagraxofusp is recommended for approval in the EU It is indicated for a rare and aggressive form of AML.
-
AML: precision treatment is safe, confers OS benefit Results are from The Beat AML Trial.
-
NICE approves new treatment for untreated chronic lymphocytic leukaemia Final draft guidance recommends first-line venetoclax plus obinutuzumab for untreated chronic lymphocytic leukaemia
-
Ph-positive ALL: chemotherapy-free first-line treatment proves highly successful Findings from the Italian GIMEMA LAL2116 D-ALBA trial.
-
Guidance on diagnosis, treatment, and follow-up are provided
-
Patient-focused approach is key to treating older patients with AML Treatment should align with the patient's goals.
-
CLL: frontline acalabrutinib shows favorable PFS and OS vs comparators Findings from a network meta-analysis.
-
Orthopedic problems in children can be the first indication of ALL ALL should be considered as a differential diagnosis in children with severe osteoporosis and vertebral fractures.
-
FDA approves azacitidine as maintenance therapy for AML The approval is based on the phase 3 QUAZAR AML-001 trial.